Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: Impact of HBV genotype G

Liver International

Volumn 32, Issue 1, 2012, Pages 93-101

  Lada, Olivier ^a   Gervais, Anne ^b   Branger, Michel ^b   Peytavin, Gilles ^b   Roquebert, Benedicte ^b   Collin, Gilles ^b   Fraqueiro, Gil ^b   Moucari, Rami ^a   Hamet, Gwen ^b   Martinot Peignoux, Michelle ^a   Matheron, Sophie ^b   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Delayed response to tenofovir; HBV genotype G; HIV HBV coinfection; Tenofovir

Indexed keywords

EMTRICITABINE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SUPERINFECTION; TREATMENT OUTCOME; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; COINFECTION; DEOXYCYTIDINE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 83255164269     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02601.x     Document Type: Article

References (51)

1. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-67.
2. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-10.
3. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 1812-22.
4. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. Aids 2005; 19: 221-40.
5. Zoulim F, Perrillo R. Hepatitis B: Reflections on the current approach to antiviral therapy. Journal of hepatology 2008; 48: S2-S19.
6. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
7. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
8. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
9. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
10. Ladner SK, Miller TJ, Otto MJ, King RW. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir Chem Chemother 1998; 9: 65-72.
11. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-6.
12. Korba BE, Schinazi RF, Cote P, Tennant BC, Gerin JL. Effect of Oral Administration of Emtricitabine on Woodchuck Hepatitis Virus Replication in Chronically Infected Woodchucks. Antimicrob. Agents Chemother. 2000; 44: 1757-1760.
13. Lim SG, Krastev Z, Ng TM, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 2006; 50: 1642-8.
14. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987; 8: 261-72.
15. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7: 161-5.
16. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92.
17. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-55.
18. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48: 1062-1069.
19. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
20. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama 2008; 300: 555-70.
21. Peytavin G, Gautran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. Eur J Clin Pharmacol 2005; 61: 267-73.
22. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69: 5437-44.
23. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
24. Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir didoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102) preliminary analysis. Hepatology 2008; 48: 370A.
25. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-6.
26. Lacombe K, Gozlan J, Boyd A, et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther 2008; 13: 705-13.
27. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39: 1062-4.
28. Eijk AA, Hansen BE, Niesters HGM, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. Journal of Viral Hepatitis 2005; 12: 364-372.
29. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J. Antimicrob. Chemother. 2005; 56: 1087-1093.
30. De Vries-Sluijs TEMS, van der Eijk AA, Hansen BE, Osterhaus ADME, de Man RA, van der Ende ME. Wild type and YMDD variant of hepatitis B virus: No difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. Journal of Clinical Virology 2006; 36: 60-63.
31. Gutierrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, Montaner JS. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. Clin Infect Dis 2008; 46: e28-30.
32. Van Bommel F, de Man RA, Stein K, et al. A Multicenter Analysis Of Aniviral Response After One Year Of Tenofovir Mono-Therapy in HBV-Monoinfected Patients With Prior Nucleos(t)ide Analog Experience. Journal of Hepatology Abstracts 73 of the 43rd Annual Meeting of the European Association for the Study of the Liver 2008;48:S33.
33. Van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006; 44: 318-25.
34. Osiowy C, Gordon D, Borlang J, Giles E, Villeneuve JP. Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol 2008; 89: 3009-15.
35. Lacombe K, Massari V, Girard PM, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. Aids 2006; 20: 419-27.
36. Lacombe K, Gozlan J, Boyd A, et al. HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection. CROI 2009 2009;Session 24 Oral Abstracts 100.
37. Alvarez-Uria G, Ratcliffe L, Vilar J. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Med 2009; 10: 269-73.
38. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-34.
39. Fung SK, Mazzulli T, Sherman M, Popovic V, Sablon S. Presenceof rtA194T at baseline does not reduce efficacy to Tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B. Hepatology 2008; 48(Suppl 1): 309A-1187A.
40. Audsley J, Arrifin N, Yuen L, et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Medicine 2009; 10: 229-235.
41. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-63.
42. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
43. Locarnini S, Warner N. The multi-drug resistant HBV RTA 181T has a secretion defect and significantly reduces the kinetics of viral rebound. Hepatology 2007; 46: 654A.
44. Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-7.
45. Alvarez-Uria G, Ratcliffe L, Vilar JF. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Medicine 2009; 10: 269-273.
46. Quiros-Roldan E, Calabresi A, Lapadula G, et al. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. Antivir Ther 2008; 13: 341-8.
47. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. Aids 2005; 19: 907-15.
48. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335: 1081-90.
49. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
50. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients. Gastroenterology 2007; 133: 1445-1451.
51. Lewin Sharon R, Ribeiro Ruy M, Avihingsanon Anchalee, et al. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 2009; 49: 1113-1121.